Bone marrow niche in the myelodysplastic syndromes

Leukemia Research

Volumn 39, Issue 10, 2015, Pages 1020-1027

  Cogle, Christopher R ^a   Saki, Najmaldin ^b   Khodadi, Elahe ^b   Li, June ^c   Shahjahani, Mohammad ^b   Azizidoost, Shirin ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow niche; Endothelial cells; Hematopoietic stem cells; Mesenchymal stem cells; Myelodysplastic syndromes

Indexed keywords

AURORA A KINASE; AURORA B KINASE; AURORA KINASE; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; FAS ANTIGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 7; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; LIPOCORTIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; OSTEONECTIN; OSTEOPONTIN; PROTEIN P53; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4;

APOPTOSIS; BONE MARROW; BONE MARROW NICHE; CELL ADHESION; CELL COMPOSITION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DNA SEQUENCE; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HIGH RISK PATIENT; HUMAN; IMMUNE EVASION; IMMUNOREGULATION; INTRACELLULAR SIGNALING; LOW RISK PATIENT; MESENCHYMAL STEM CELL; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; STEM CELL NICHE; UPREGULATION; HEMATOPOIETIC STEM CELL; MESENCHYMAL STROMA CELL; PATHOLOGY; PHYSIOLOGY;

BONE MARROW; HEMATOPOIETIC STEM CELLS; HUMANS; MESENCHYMAL STROMAL CELLS; MYELODYSPLASTIC SYNDROMES; STEM CELL NICHE;

EID: 84941315837     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.06.017     Document Type: Review

References (62)

1. Adès L.I.R., Fenaux P. Myelodysplastic syndromes. Lancet 2014, 383:2239-2252.
2. Mufti G.J. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract. Res. Clin. Haematol. 2004, 17:543-557.
3. Parker J.E., Mufti G.J., Rasool F., et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000, 96:3932-3938.
4. Raaijmakers Marc H.G.P., Mukherjee S., Guo S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukemia. Nature 2010, 464(7290):852-857.
5. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-65.
6. Blau O., Baldus C.D., Hofmann W.K., et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011, 118:5583-5592.
7. Konopleva M., Tabe Y., Zeng Z., et al. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updates 2009, 12(4):103-113.
8. Zhao Z.G., Xu W., Yu H.P., et al. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett. 2012, 317:136-143.
9. Shiozawa Y., Havens A.M., Pienta K.J., et al. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008, 22:941-950.
10. Miura Y., Gao Z., Miura M., et al. Mesenchymal stem cell-organized bone marrow elements: an alternative hematopoietic progenitor resource. Stem Cells 2006, 24:2428-2436.
11. Taichman R.S., Emerson S.G. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J. Exp. Med. 1994, 179:1677-1682.
12. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br. J. Haematol. 2008, 142(5):695-708.
13. Li J. Myelodysplastic syndrome hematopoietic stem cell. Int. J. Cancer 2013, 133:525-533.
14. Raaijmakers M.H.G.P. Disease progression in myelodysplastic syndromes: do mesenchymal cells pave the way?. Cell Stem Cell 2014, 14:695-697.
15. Oliveiraa F.M., Lucena-Araujoa A.R., et al. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with sG-banding analysis and FISH. Exp. Hematol. 2013, 41:198-208.
16. Nigg E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2001, 2:21-32.
17. Li D., Zhu J., Firozi P.F., et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin. Cancer Res. 2003, 9:991-997.
18. Vader G., Lens S.M. The Aurora kinase family in cell division and cancer. Biochim. Biophys. Acta 2008, 1786:60-72.
19. Tatsuka M., Sato S., Kitajima S., et al. Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 2005, 24:1122-1127.
20. Blau O., Hofmann W.K., Baldus C.D., et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp. Hematol. 2007, 35:221-229.
21. Najar M., Raicevic G., Boufker H., et al. Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Exp. Hematol. 2010, 38:922-932.
22. Nicola M., Di, Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
23. Kastrinaki M.C., Pavlaki K., Batsali A.K., et al. Mesenchymal stem cells in immune-mediated bone marrow failure syndromes. Clin. Dev. Immunol. 2013, 10:1-10.
24. Azizdoost S., Babashah S., Rahim F., et al. Bone marrow neoplastic niche in leukemia. ISH 2013, 10:1-8.
25. Raaijmakers M.H., Mukherjee S., Guo S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
26. Santamaria C., Muntion S., Roson B., et al. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 2012, 97:1218-1224.
27. Boocock G.R. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat. Genet. 2003, 33:97-101.
28. Saki N., Abroun S., Farshdousti Hagh M., et al. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell J. 2011, 13:131-136.
29. Taichman R.S., Emerson S.G. The role of osteoblasts in the hematopoietic microenvironment. Stem Cells 1998, 16:7-15.
30. Zhu J., Garrett R., Jung Y., et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood 2007, 109:3706-3712.
31. Taichman R.S., Reilly M.J., Emerson S.G., et al. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood 1996, 87:518-524.
32. Borojevic R., Roela R.A., Rodarte R.S., et al. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leuk. Res.. 2004, 28:831-844.
33. Yan Q., Sage E.H. SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 1999, 47(12):1495-1506.
34. Jung Y., Wang J., Song J., et al. Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood 2007, 110:82-90.
35. Nilsson S.K., Johnston H.M., Whitty G.A., et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005, 106:1232-1239.
36. Zhang J., Niu C., Ye L., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
37. Kiel M.J., Radice G.L., Morrison S.J., et al. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell 2007, 1:204-217.
38. Sacchetti B., Funari A., Michienzi S., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131:324-336.
39. Huang M., Zhu J. The regulation of normal and leukemic hematopoietic stem cells by niches. Cancer Microenviron. 2012, 5:295-305.
40. Dar A., Goichberg P., Shinder V., et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat. Immunol. 2005, 6:1038-1046.
41. Flores-Figueroa E., Gutierrez-Espindola G., Montesinos J.J., et al. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk. Res. 2002, 26:677-686.
42. Geyh S., Oz S., Cadeddu R.P. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013, 27:1841-1851.
43. Fozza C., Longinotti M. The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers. Leuk. Res. 2013, 37:201-203.
44. Yamazaki S., Nakauchi H. Insights into signaling and function of hematopoietic stem cells at the single-cell level. Curr. Opin. Hematol. 2009, 16:255-258.
45. Bellini O., Casazza A.M., di Marco A., et al. Histological and histochemical studies of myocardial lesions in BALBc/Cr mice. Lab. Anim. Sci. 1976, 26:329-333.
46. Campioni D., Punturieri D., Bardi A., et al. In vitro evaluation of bone marrow angiogenesis in myelodysplastic syndromes: a morphological and functional approach. Leuk. Res. 2004, 28:9-17.
47. Bellamy W.T., Richter L., Sirjani D., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427.
48. van Kamp H., Fibbe W.E., Jansen R.P., et al. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood 1992, 80:1774-1780.
49. Cogle C.R., Goldman D.C., Madlambayan G.J., Leon R.P., Al Masri A., Clark H.A., et al. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia 2014, 28(10):1978-1987.
50. Cogle C.R., Bosse R.C., Brewer T., Migdady Y., Shirzad R., Kampen K.R., et al. Acute myeloid leukemia in the vascular niche. Cancer Lett. 2015.
51. Korkolopoulou P., Apostolidou E., Pavlopoulos P.M., et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 2001, 15:1369-1374.
52. Raza A., Gezer S., Mundle S., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndrome. Blood 1996, 86:268.
53. Olsson A.K., Dimberg A., Kreuger, et al. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
54. Bellamy W.T., Richter L., Sirjani D., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427-1434.
55. Wimazal F., Krauth M.T., Vales A., et al. Immunohistochemical detection of vascular endothelial growth factor () in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk. Lymphoma. 2006, 47:451-460.
56. Scott L.M., Rebel V.I. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. J. Natl. Cancer Inst. 2013, 105(20):1540-1549.
57. Smith A.E., Mohamedali A.M., Kulasekararaj A., Lim Z., Gäken J., Lea N.C., et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010, 116(19):3923-3932.
58. Haferlach T., Nagata Y., Grossmann V., Okuno Y., Bacher U., Nagae G., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28(2):241-247.
59. Cogle C.R., Iannacone M.R., Yu D., Cole A.L., Imanirad I., Yan L., et al. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk. Res. 2014, 38(1):71-75.
60. Genovese G., Kähler A.K., Handsaker R.E., Lindberg J., Rose S.A., Bakhoum S.F., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 2014, 371(26):2477-2487.
61. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112(1):45-52.
62. Xie M., Lu C., Wang J., McLellan M.D., Johnson K.J., Wendl M.C., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Med. 2014, 20(12):1472-1478.